H2020HORIZONFP7
Fundacio Privada Institut D'Investigacio Oncologica de Vall-Hebron (Vhio)
- Country
- ESSpain
- Defence projects
- 0
- Projects, all programmes
- 49
- As coordinator
- 18
- EU contribution (CORDIS)
- EUR 24,703,576
- Active
- 2008 to 2025
Projects
49 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| H2OH2O Health Outcomes Observatory | H2020 | 2020 | Third party | Not stated |
| oncNGSNGS diagnostics in 21st century oncology: the best, for all, at all times | H2020 | 2020 | Participant | EUR 48,312 |
| EURAMED rocc-n-rollEURopeAn MEDical application and Radiation prOteCtion Concept: strategic research agenda aNd ROadmap interLinking to heaLth and digitisation aspects | H2020 | 2020 | Participant | EUR 35,000 |
| AR-DDRCo-targeting androgen receptor signalling and DNA damage repair for precision therapy in advanced prostate cancer | H2020 | 2019 | Coordinator | EUR 172,932 |
| EUCANCanEUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine. | H2020 | 2019 | Participant | EUR 343,688 |
| COLOSSUSAdvancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions | H2020 | 2018 | Participant | EUR 986,983 |
| EDIReXEurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts | H2020 | 2018 | Participant | EUR 517,595 |
| SYST-iMYCDevelopment of an effective and safe systemic Myc inhibitor for the treatment of multiple cancer types. | H2020 | 2018 | Coordinator | EUR 148,875 |
| MESI-STRATSystems Medicine of Metabolic-Signaling Networks: A New Concept for Breast Cancer Patient Stratification | H2020 | 2018 | Participant | EUR 220,099 |
| HARMONYHealthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 | H2020 | 2017 | Participant | EUR 156,308 |
| Wnt and CRCTherapeutic inhibition of the oncogenic Wnt/beta-catenin pathway in mismatch repair deficient hypermutant tumors | H2020 | 2017 | Coordinator | EUR 170,122 |
| GBM-CPPDeveloping an anti-Myc cell-penetrating peptide for cancer treatment | H2020 | 2016 | Coordinator | EUR 147,750 |
| NoCanTherNanomedicine upscaling for early clinical phases of multimodal cancer therapy | H2020 | 2016 | Participant | EUR 347,979 |
| CSC-ISDevelopment of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour’s immune system. | H2020 | 2015 | Coordinator | EUR 150,000 |
| MoTriColorMolecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) | H2020 | 2015 | Coordinator | EUR 1,049,063 |
| MedBioinformaticsCreating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities (MedBioinformatics) | H2020 | 2015 | Participant | EUR 186,000 |
| PhdDeciphering PI3K biology in health and disease | H2020 | 2015 | Participant | EUR 247,873 |
| MYCINHIBINCLINICPushing Myc inhibition towards the clinic | FP7 | 2014 | Coordinator | EUR 1,730,700 |
| WINTHERWINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients | FP7 | 2013 | Participant | EUR 147,952 |
| MERCURICA Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients. | FP7 | 2013 | Participant | EUR 230,041 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.